Alpha Tau Medical Ltd
DRTSHealthcare|Biotechnology|IL
$13.72
+0.42 (+3.16%)
Tangible Book / Share
$0.48
Cash / Share
$1.11
About
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Stock Price
+261.1%(1Y)
1M
-2.0%
3M
+4.4%
6M
+61.2%
YTD
+177.2%
1Y
+250.0%
3Y
+341.2%
5Y
+38.3%
Pipeline Summary
30 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 14Completed: 6Active: 4Unknown: 2Not Yet Recruiting: 2Terminated: 2
Active Trials (18)
A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients.
NCT06202118Breast Cancer
N/ARecruiting
Enrollment: 10 participants
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NCT06698458Pancreatic Cancer
N/AActive
Enrollment: 50 participants
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer
NCT05632913Recurrent Lung Cancer
N/ARecruiting
Enrollment: 10 participants
Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer
NCT06026943Pancreatic Cancer
N/ARecruiting
Enrollment: 15 participants
Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer
NCT06755359Pancreatic Cancer
N/ARecruiting
Enrollment: 40 participants
Key Facts
Market Cap$1.27B
Employees121
CEOUzi Sofer
IPO DateMar 8, 2021
Beta1.29
52-Week Range$3.43 – $15.79
Avg Volume575,899
ExchangeNASDAQ
Websitealphatau.com
Ownership
Float69.3%
Shares Outstanding92.5M
Recent Insider Trades
Levy RaphiOPTION EX.
Aug 21, 20262,871 shares @ $2.98
Levy RaphiSELL
Aug 21, 20262,871 shares @ $15.00
Levy RaphiOPTION EX.
Aug 11, 202617,730 shares @ $2.98
Levy RaphiSELL
Aug 11, 202617,730 shares @ $14.00
Levy RaphiOPTION EX.
Jul 6, 20262,270 shares @ $2.98
Peers
Recent News
Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange
Oct 29, 2026 · globenewswire.com
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
Oct 22, 2026 · globenewswire.com
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
Oct 19, 2026 · globenewswire.com
Alpha Tau to Participate in October Investor Conferences
Oct 5, 2026 · globenewswire.com
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More
Sep 11, 2026 · seekingalpha.com
Data last updated: Nov 9, 2026, 04:07 AM